About the Authors

  • The Authors and Contributors of "Patent Docs" are patent attorneys and agents, many of whom hold doctorates in a diverse array of disciplines.
2018 Juristant Badge - MBHB_165
Juristat #4 Overall Rank

E-mail Newsletter

  • Enter your e-mail address below to receive the "Patent Docs" e-mail newsletter.

Enter your email address:

Delivered by FeedBurner

Contact the Docs

Docs on Twitter


Disclaimer

  • "Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorney-client relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.
Juristat_165
Juristat #8 Overall Rank

Pharma-50-transparent_216px_red

« Quanta Computer, Inc. v. LG Electronics, Inc. (2008) | Main | Will Biotechnology Solve the World Food Crisis? »

June 10, 2008

Comments

Are there any indications (perhaps in the earlier filed comments) that anyone might file for an injunction?

T:

I have not heard of anyone that has expressed an interest in taking on the Tafas/GSK role with respect to the new appeals rules. As I mentioned in my post, it may be that these rules are just not as controversial as the now enjoined continuation and claims rules, or the still-pending IDS and Markush rules packages.

Don

The comments to this entry are closed.

March 2020

Sun Mon Tue Wed Thu Fri Sat
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31